Phase I dose-escalating trial of Escherichia coli purine nucleoside phosphorylase and fludarabine gene therapy for advanced solid tumors(†)

BACKGROUND: The use of Escherichia coli purine nucleoside phosphorylase (PNP) to activate fludarabine has demonstrated safety and antitumor activity during preclinical analysis and has been approved for clinical investigation. PATIENTS AND METHODS: A first-in-human phase I clinical trial (NCT 013101...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Ann Oncol
Prif Awduron: Rosenthal, E. L., Chung, T. K., Parker, W. B., Allan, P. W., Clemons, L., Lowman, D., Hong, J., Hunt, F. R., Richman, J., Conry, R. M., Mannion, K., Carroll, W. R., Nabell, L., Sorscher, E. J.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Oxford University Press 2015
Pynciau:
Original Articles
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4560028/
https://ncbi.nlm.nih.gov/pubmed/25899782
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdv196
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg